Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.

Lin LiuDongsheng HongKuifen MaXiaoyang Lu

Published in: Journal of clinical pharmacy and therapeutics (2020)

The existing evidence supports the cost-effectiveness of rivaroxaban therapy as an alternative anticoagulant to warfarin for patients with NVAF at different renal function levels.

Keyphrases

atrial fibrillation
oral anticoagulants
direct oral anticoagulants
catheter ablation
left atrial
left atrial appendage
heart failure
venous thromboembolism
percutaneous coronary intervention
mesenchymal stem cells
aortic valve
mitral valve